Ignite Creation Date:
2024-05-05 @ 5:30 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00472927
Status:
COMPLETED
Last Update Posted:
2007-12-06
First Post:
2007-05-10
Brief Title:
Bioequivalence Study of 3 New Formulations of PremarinMPA Compared With PremarinMPA Prempro
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
An Open-Label Single-Dose Randomized 4-Period Crossover Bioequivalence Study of Three New Formulations of Premarin 045mgMedroxyprogesterone Acetate MPA 15mg Compared With a Reference Formulation of PremarinMPA PremproTM 045mg15mg in Healthy Postmenopausal Women
Status:
COMPLETED
Status Verified Date:
2007-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate three new investigational tablet formulations of the Food and Drug Administration FDA approved medication Prempro Premarin combined with medroxyprogesterone acetate MPA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None